←
Dr. James Underberg22,421 posts
Dr. James Underberg avatar

Dr. James Underberg

@lipiddoc

Lipidologist🩺🧬 @nyulangone @NYUCVDPrevent PastPresident @NationalLipid & @LipidBoard President @NLAFoundation Dir. @BHLipidClinic T/RT≠endorsements/med advice

◷ Joined May 2009▧ 2,018 Photos and videos
National Lipid Association avatar
⟳ Dr. James Underberg retweeted
National Lipid Association@nationallipid·Sep 25

In honor of #CholesterolMonth, the NLA is proud to release the second installment of the Lipids Simplified Series: Lipoprotein(a) Management Simplified. Following the success of our LDL-C Management Simplified publication, we felt there was no more timely or necessary topic to tackle next than Lp(a). Authored by leading Lp(a) experts Marlys L. Koschinsky, PhD, FNLA and Christie M. Ballantyne, MD, MNLA, this article and accompanying infographic are designed to distill the complexity surrounding Lp(a) into clear, actionable guidance for clinicians. Our goal is simple: make this essential science more accessible and easier to apply in everyday practice. 🔗 Access the full article and infographic at lipid.org/resource/lipoprote…. 👉 You can find this and other NLA articles under the Articles section of our newly launched lipid.org. Stay tuned... more topics in the Lipids Simplified Series are on the way! #LipoproteinA #Lpa #ASCVD #CardiovascularPrevention @CBallantyneMD @MarlysLPA

Post attachmentPost attachmentPost attachment
NYU CVD Prevention avatar
⟳ Dr. James Underberg retweeted
NYU CVD Prevention@NYUCVDPrevent·Jul 7

Congratulations to Edward A. Fisher, MD, PhD, on being selected to deliver the Russell Ross Memorial Lectureship in Vascular Biology at #AHA26 this November in Chicago. This well-deserved honor recognizes Dr. Fisher's exceptional contributions to vascular biology.

Post attachment
Dr. James Underberg avatar
Dr. James Underberg@lipiddoc·Aug 6

The Lp(a) story gets more interesting every day ! Wonderful paper @Lpa_Doc

We've long focused on Lp(a) molar concentration, but Lp(a) biology is more complex. In our new paper led by Kaloyan Takov and Manual Mayr @Vascular_Prot, shows that native Lp(a) carries an APOE-associated triglyceride signature. TG(52:3) and TG(52:4), enriched in polyunsaturated fatty acids, are linked to incident MACE and may represent oxidizable lipid cargo contributing to cardiovascular risk. Lots of new stuff on the way identifying specific components of Lp(a) (chol, TG, OxPL) and CVD risk @DavidErlinge @GreggWStone @society_eas atherosclerosis-journal.com/…

Post attachment
Dr. James Underberg avatar
Dr. James Underberg@lipiddoc·Jul 31

Long-term treatment of homozygous familial hypercholesterolemia with lomitapide: 11 years of safety and effectiveness findings from the Lomitapide Observational Worldwide Evaluation Registry (LOWER) - Journal of Clinical Lipidology lipidjournal.com/article/S19… via @LipidJournal @NYUCVDPrevent @FamilyHeartFdn @foundationofnla #HoFH #FindFH

National Lipid Association avatar
⟳ Dr. James Underberg retweeted
National Lipid Association@nationallipid·Jul 27

A topic at the forefront of lipidology: the VESALIUS-CV trial.🔬 In a new Roundtable published in @lipidjournal, Drs. Nicholas A. Marston, Robert P. Giugliano, and Kevin C. Maki dive deep into VESALIUS-CV and other clinical trials investigating intensive LDL-C reduction in high-risk patients. Together, they touch on the study designs, results, and what it all means for clinical practice. A must-read for any clinician managing cardiovascular risk. 🔗 lipidjournal.com/article/S19… The conversation continues at #NLAFall, October 2–4 in Orlando, where the latest clinical trial data takes center stage. 🔗 lipid.org/fall @SystematicIRE #Lipidology #VESALIUS #CardiovascularPrevention #CardiometabolicHealth

0:58
Thomas Dayspring avatar
⟳ Dr. James Underberg retweeted
Thomas Dayspring@Drlipid·Jul 16

THE LIPID THERAPEUTIC WORLD just changed. The first ORAL PCK9 inhibitor enlicitide, made by Merck, and sold as Lipfendra has arrived. Be sure to become familiar with how patients should take it. Its monthly price seems a bit lower than the injectables. The F.D.A. Approves a New Pill to Slash Cholesterol Levels nytimes.com/2026/07/16/scien… @nationallipid @ASPCardio @TheEndoSociety @FamilyHeartFdn @society_eas

Dr. James Underberg avatar
Dr. James Underberg@lipiddoc·Jul 2

Very excited to see so much interest in the field of CV Prevention and Lipidology Welcome Josh ! @NYUCVDPrevent @nationallipid @lipidboard

We’re thrilled to welcome Dr. Joshua Hyman as our newest Preventive Cardiology Fellow-the 17th fellow in our program’s history! Dr. Hyman earned his medical degree at Yale and recently completed the Yale Internal Medicine-Pediatrics Residency Program. med.nyu.edu/departments-inst…

0:05
Dr. James Underberg avatar
Dr. James Underberg@lipiddoc·Jun 24

Very exciting news for patients with SHTG - another option to lower triglycerides @foundationofnla @NYUCVDPrevent @Drlipid @dan_soffer

Lipid News📢: TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG). Read the full announcement from @ionispharma: ir.ionis.com/news-releases/n…

National Triglyceride Alliance avatar
⟳ Dr. James Underberg retweeted
National Triglyceride Alliance@NatTgAlliance·Mar 19

One year of impact—and we’re just getting started. The National Triglyceride Alliance was founded on a simple idea: triglycerides deserve more attention as a critical driver of cardiovascular and metabolic health. Since then? ✔️ A growing national coalition ✔️ New education and clinical resources ✔️ Expanded awareness for patients and providers As we approach #NationalTriglyceridesDay (March 28), we’re reminded that progress starts with awareness—and continues with action. Let’s keep pushing forward. Read the press release: ow.ly/NPoz50YwlrN @SethJBaumMD @EliotBrinton @mmillermd1 @lipiddoc @ArchnaBajajMD @drmaggarwal @nationallipid @ASPCardio @NatPancFdn @livingwithfcs @TheAACE @HeartNurses @ionispharma @ArrowheadPharma @Amarincorp #Triglycerides #Cardiology #MedEd #HealthcareInnovation

Pablo Corral MD avatar
⟳ Dr. James Underberg retweeted
Pablo Corral MD@drpablocorral·Mar 13

🙌 Today the 2026 ACC/AHA Guideline on the Management of Dyslipidemia has been released. 📍Key updates shaping contemporary lipid management: 1️⃣ Lp(a) measurement is now recommended at least once in all adults for ASCVD risk assessment. 2️⃣ PREVENT equations replace the Pooled Cohort Equations for estimating 10-year and 30-year ASCVD risk. 3️⃣ LDL-C and non-HDL-C treatment goals return as central therapeutic targets alongside percentage LDL reduction. 4️⃣ Earlier intervention is emphasized to reduce lifelong exposure to atherogenic lipoproteins. 5️⃣ Broader integration of ApoB, CAC scoring, and modern lipid-lowering therapies to refine risk stratification and treatment. 👆 An important step forward in translating decades of lipid research into clinical practice and cardiovascular prevention. 🔓 Open Access 🔗 jacc.org/doi/10.1016/j.jacc.… @nationallipid @society_eas

Post attachment
National Lipid Association avatar
⟳ Dr. James Underberg retweeted
National Lipid Association@nationallipid·Mar 13

The 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia is here, and the NLA is proud to be among the collaborating organizations. This landmark guideline addresses evaluation, management, and monitoring of elevated cholesterol, triglycerides, and Lp(a); restores LDL-C treatment goals based on risk; and provides guidance for both adults and children across all stages of prevention. Read the full guideline: jacc.org/doi/10.1016/j.jacc.… Read the NLA's press release: lipid.org/nla/2026-accahamul… #Lipidology #Dyslipidemia #Cholesterol #CardiovascularHealth

Post attachment
Foundation of the NLA avatar
⟳ Dr. James Underberg retweeted
Foundation of the NLA@foundationofnla·Feb 4

This Rare Disease Month, we’re cheering for patients on and off the field. And, tailgating the big game doesn’t have to mean high fat.🏈 Our new Buffalo Chicken Dip is low fat but still packed with flavor. So, everyone wins, no matter which team you’re cheering for!😉

0:37